New drugs beyond biologics in rheumatoid arthritis: the kinase inhibitors

Rheumatology (Oxford). 2011 Sep;50(9):1542-50. doi: 10.1093/rheumatology/ker192. Epub 2011 May 26.


Orally available small molecule compounds have recently been developed for the treatment of RA, and inhibitors of signalling cascades, specifically inhibitors of kinases, have reached advanced stages of clinical development. The p38 mitogen-activated protein kinase blockers have shown poor clinical response despite encouraging preclinical data. In contrast, inhibitors of the non-receptor tyrosine kinases, spleen tyrosine kinase and janus kinase 3, have demonstrated a significant clinical efficacy together with an acceptable safety profile. We herein present a review on published preclinical and clinical data on these new drugs.

Publication types

  • Review

MeSH terms

  • Agammaglobulinaemia Tyrosine Kinase
  • Animals
  • Arthritis, Rheumatoid / drug therapy*
  • Arthritis, Rheumatoid / metabolism
  • Cytokines / metabolism
  • Humans
  • Intracellular Signaling Peptides and Proteins / antagonists & inhibitors*
  • Janus Kinases / antagonists & inhibitors*
  • Mitogen-Activated Protein Kinase 14 / antagonists & inhibitors*
  • Protein Kinase Inhibitors / adverse effects
  • Protein Kinase Inhibitors / therapeutic use*
  • Protein-Tyrosine Kinases / antagonists & inhibitors*
  • Syk Kinase


  • Cytokines
  • Intracellular Signaling Peptides and Proteins
  • Protein Kinase Inhibitors
  • Protein-Tyrosine Kinases
  • Agammaglobulinaemia Tyrosine Kinase
  • Janus Kinases
  • SYK protein, human
  • Syk Kinase
  • Mitogen-Activated Protein Kinase 14